Veracyte to Participate in Upcoming Investor Conferences

February 19, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 19, 2026-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences.

- **Raymond James 47th Annual Institutional Investors Conference – Orlando, FL**
  Presentation on March 3rd at 8:05 a.m. Eastern Time
- **Leerink Partners Global Health Conference – Miami, FL**
  Fireside chat on March 9th at 10:40 a.m. Eastern Time

Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260219711059/en/

Investors:
Shayla Gorman
investors@veracyte.com

Media:
Molly Cornbleet
media@veracyte.com

Source: Veracyte, Inc.